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ABSTRACT
Glial vulnerability to prions is assessed in murine Creutzfeldt-Jakob disease (CJD) using the tg340 
mouse line expressing four-fold human PrP M129 levels on a mouse PrP null background at 
different days following intracerebral inoculation of sCJD MM1 brain tissues homogenates. The 
mRNA expression of several astrocyte markers, including glial fibrillary acidic protein (gfap), 
aquaporin-4 (aqp4), solute carrier family 16, member 4 (mct4), mitochondrial pyruvate carrier 1 
(mpc1) and solute carrier family 1, member 2 (glial high-affinity glutamate transporter, slc1a2) 
increases at 120 and 180 dpi. In contrast, the mRNA expression of oligodendrocyte and myelin 
markers oligodendrocyte transcription factor 1 (olig1), olig2, neural/glial antigen 2 (cspg), solute 
carrier family 16, member 1 (mct1), myelin basic protein (mbp), myelin oligodendrocyte glycopro-
tein (mog) and proteolipid protein 1 (plp1) is preserved. Yet, myelin regulatory factor (myrf) mRNA 
is increased at 180 dpi. In the striatum, a non-significant increase in the number of GFAP-positive 
astrocytes and Iba1-immunoreactive microglia occurs at 160 dpi; a significant increase in the 
number of astrocytes and microglia, and a significant reduction in the number of Olig2- 
immunoreactive oligodendrocytes occur at 180 dpi. A decrease of MBP, but not PLP1, immunor-
eactivity is also observed in the striatal fascicles. These observations confirm the vulnerability and 
the reactive responses of astrocytes, together with the microgliosis at middle stages of prion 
diseases. More importantly, these findings show oligodendrocyte vulnerability and myelin altera-
tions at advanced stages of murine CJD. They confirm oligodendrocyte involvement in the 
pathogenesis of CJD.
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Prion diseases are fatal neurodegenerative diseases linked 
to the transformation of normal prion protein (PrPC) into 
an abnormal prion protein (PrPRes) which is transmitted 
from one cell to another causing neuron loss, astrocytic 
gliosis, microglia activation, and, frequently, spongiform 
change. This transformation leads to devastating effects on 
the central nervous system including abnormal behaviour 
in animals, and cognitive impairment and rapid dementia 
in humans. Creutzfeldt-Jakob disease (CJD) and scrapie 
are the most common natural paradigms of sporadic prio-
nopathies in humans, and sheep and goats, respectively [1– 
4]. CJD can be categorized depending on the prion type 
and the phenotype of codon 129 in PRNP; sporadic CJD 
methionine/methionine type 1 (sCJD MM1) is the most 
common form of CJD [5,6].
PrPC modulates the differentiation of stem-cells to 
neurons, astrocytes, and oligodendrocytes during 
development [7,8]. In contrast to other neural cell 
types, oligodendrocytes are considered resistant to 
prions [9]. However, a putative trans-membrane 
domain of the human PrPC induces apoptosis of oligo-
dendrocytes in vitro in a time- and dose-dependent 
manner [10]. PrPRes immunoreactivity is observed as 
arrays adjacent to myelinated fibres and as clumps 
adjacent to oligodendroglial nuclei in the cerebrum 
and cerebellum in sCJD [11]. Large, PrPRes- 
immunoreactive perinuclear and nuclear deposits may 
occur in oligodendrocytes in a few cases with sCJD 
[12]. Morphological observations are complemented 
by biochemical studies showing reduced expression of 
a few oligodendrocyte cell markers in the cerebral cor-
tex at the terminal stages of sCJD [13]. The present 
study was designed to assess the involvement of oligo-
dendrocytes and astrocytes at preclinical and clinical 
stages in tg340 mice inoculated with human brain 
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homogenates of sCJD. The study was aimed at gaining 
information about oligodendrocyte and astrocyte vul-
nerability at preclinical stages and with disease progres-
sion in a validated model of experimental CJD.
Material and methods
The tg340 mouse line expressing about four-fold level 
of human PrP M129 on a mouse PrP null background 
was generated as described elsewhere [14]. Inocula were 
prepared from sCJD MM1 brain tissues as 10% (w/v) 
homogenates. Mice aged 6–10 weeks old were anaes-
thetised and inoculated in the frontal cortex using a 25- 
gauge disposable hypodermic needle, as detailed else-
where [15] (four-six animals per group and time point). 
Mice were observed daily and the neurological status 
was assessed weekly. Mice were euthanized at 0, 60, 120 
(pre-clinical), 160, and 180 (clinical) days post- 
inoculation (dpi), necropsy was performed, and the 
brain was rapidly removed. One hemisphere was fixed 
by immersion in 4% buffered formalin; the other was 
frozen at −80°C and stored at this temperature until 
use. The samples fixed in buffered formalin were then 
transferred to a solution of formic acid, washed, and 
embedded in paraffin. Unfortunately, not all samples 
were available for biochemical and morphological stu-
dies due to unexpected accidental events. Biochemical 
studies were limited to mRNA expression as not 
enough material was available for western blot studies 
on account of the same reasons. All animal experiments 
were performed in compliance with institutional and 
French national guidelines in accordance with the 
European Union Directives 86/609/EEC and 2010/63/ 
EU. Experiments were approved by the Committee on 
the Ethics of Animal Experiments of the author’s insti-
tutions: INRA Toulouse/ENVT (Permit Number: 
01734.01).
Gene expression was analysed at 120, 160, and 180 
dpi, and corresponding age-matched controls; morphol-
ogy and immunohistochemistry at 0, 60, 120, and 180 
dpi, and corresponding controls. We used the miRvana 
isolation kit (Ambion, USA) to obtain RNA of sCJD 
MM1 mice and controls. Then, samples were treated 
with RNase-free DNase set (Ambion, US) for 30 min to 
avoid the extraction and subsequent amplification of 
genomic DNA. The concentration of each sample was 
determined at 340 nm using NanoDrop 2000 spectro-
photometer (Thermo Scientific, USA). High Capacity 
cDNA Archive kit (Applied Biosystems, US) following 
the protocol provided by the manufacturer and using the 
Gene Amp® 9700 PCR System thermocycler (Applied 
Biosystems, USA) was used for the retrotranscriptase 
reaction of RNA samples. A parallel reaction for an 
RNA sample was run in the absence of reverse transcrip-
tase to assess the degree of contaminating genomic DNA. 
PCR assays were conducted in duplicate on cDNA sam-
ples obtained from the retrotranscription reaction and 
diluted 1:15 in 384-well optical plates (Applied 
Biosystems, USA) utilizing an ABI Prism 7900 
Sequence Detection System (Applied Biosystems, USA). 
Parallel amplification reactions for each sample were 
carried out using the 20× TaqMan Gene Expression 
Assays (Applied Biosystems, USA) and 2× TaqMan 
Universal PCR Master Mix (Applied Biosystems, USA). 
We used the internal housekeeping genes alanyl-tRNA 
synthetase (aars), β-glucuronidase (gusβ), and X-prolyl 
aminopeptidase P1 (xpnpep1) for normalization. Probes 
used in this study are shown in Table 1. The reactions 
were performed as follows: 50°C for 2 min, 95°C for 10  
min, and 40 cycles of 95°C for 15 s, and 60°C for 1 min. 
TaqMan PCR data were captured using the Sequence 
Detector Software (SDS version 2.1, Applied 
Biosystems, USA). We used the double-delta cycle 
threshold (ΔΔCT) method to analyse the results. ΔΔCT 
values were calculated as the ΔCT of each test sample 
minus the mean ΔCT of the calibrator samples for each 
target gene. The fold change was determined using the 
equation 2(−ΔΔCT).
Formalin-fixed, formic acid-treated, paraffin- 
embedded de-waxed sections, 4 μm thick, were stained 
with haematoxylin and eosin, or processed for immuno-
histochemistry. The sections were boiled in citrate buffer 
(20 min). Endogenous peroxidases were blocked by incu-
bation in 10% methanol-1% H2O2 solution (15 min) 
followed by 3% normal horse serum solution. Then, the 
sections were incubated at 4°C overnight with one of the 
primary antibodies against glial fibrillary acidic protein 
(GFAP) (rabbit polyclonal, used at 1:500, Dako, Glostrup, 
Table 1. List of taqman probes used in gene expression studies.
Gene Full name Reference
aars alanyl-tRNA synthetase Mm00507627_m1
aqp4 Aquaporin-4 Mm00802131_m1
cspg4 Neural/glial antigen 2 Mm00507257_m1
gfap Glial fibrillary acidic protein Mm01253033_m1
gus-β β-glucuronidase Mm01197698_m1
mbp Myelin Basic Protein Mm01266402_m1
mct1 Solute Carrier Family 16 (Monocarboxylic 
Acid Transporters), Member 1
Mm01306379_m1
mct4 Solute Carrier Family 16 (Monocarboxylic 
Acid Transporters), Member 4
Mm01246825_m1
mog Myelin Oligodendrocyte Glycoprotein Mm01279062_m1
mpc1 Mitochondrial Pyruvate Carrier 1 Mm01316203_g1
myrf Myelin Regulatory Factor Mm01194959_m1
olig1 Oligodendrocyte Transcription Factor 1 Mm00497537_s1
olig2 Oligodendrocyte Lineage Transcription 
Factor 2
Mm01210556_m1
plp1 Proteolipid Protein 1 Mm01297210_m1
slc1a2 Solute Carrier Family 1 (Glial High Affinity 
Glutamate Transporter), Member 2
Mm01275814_m1




DK), Olig-2 (rabbit polyclonal, used at 1:500, Abcam, 
Cambridge, UK), Iba1 (rabbit polyclonal, used at 
1:1,000, Wako, Osaka, Japan), MBP (rabbit polyclonal, 
used at 1:500, Dako, Glostrup, DK), PLP1 (mouse mono-
clonal, used at 1:100, LSBio, Seattle, WA, USA) and PrP 
(mouse monoclonal, used at 1:50, BioReagents Tech., 
France) with and without pre-incubation with proteinase 
K. Following incubation with the primary antibody, the 
sections were incubated with EnVision + system perox-
idase (Dako, DK) for 30 min at room temperature. The 
peroxidase reaction was visualized with diaminobenzi-
dine and H2O2. Control of the immunostaining included 
omission of the primary antibody; no signal was obtained 
following incubation with only the secondary antibody. 
Peptides for pre-absorption studies were not available.
Quantifications of GFAP-, Olig2-, and Iba1-immu-
noreactive cells in the anterior striatum were made by 
counting the number of positive cells in three areas 
per section of the anterior striatum selected at ran-
dom measuring 0.05 mm2 each, one section per 
mouse, and all mice at the different dpi using 
a DP25 camera adapted to an Olympus BX50 light 
microscope. The number of positive cells was counted 
directly on the figures and expressed as the number of 
positive cells per area. The density of MBP was calcu-
lated in three areas per section of the anterior stria-
tum selected at random measuring 0.162 mm2 each, 
one section per mouse, and for all mice at the differ-
ent dpi. Densitometry was calculated using the 
Analysis tool of the Adobe® Photoshop® CS5 software 
(Adobe Systems Inc., San Jose, CA, USA). The density 
of MBP was calculated as the intensity of brown 
colour normalized for the total area excluding white 
spaces of the nuclei and expressed as arbitrary units 
per area. Quantifications and densitometry were per-
formed by a researcher blind to the corresponding 
MM1-inoculation or incubation time of each section.
Statistical analysis was performed with the SPSS 
Statistics v21.0 software (IBM Corp. Released 2013, IBM- 
SPSS Statistics for Windows, Version 21.0., Armonk, NY, 
USA). The normality of distribution was analysed with 
the Kolmogorov–Smirnov test. Gene expression data 
were analysed with two-way analysis of variance 
(ANOVA) with MM1-inoculation and incubation time 
as between factors, followed by Bonferroni’s post hoc test 
when required. The data were expressed as mean ± SEM. 
Differences between the control group and its respective 
inoculated group were considered statistically significant 
at *p < 0.05, **p < 0.01, ***p < 0.001.
Densitometry and quantification data were analysed 
with one-way ANOVA followed by Tukey’s post-hoc to 
compare inoculum incubation times. The data were 
expressed as mean ± SEM. Differences between 
inoculated groups at different incubation times were 
set at **p < 0.01, ***p < 0.001 vs. 0 dpi; ## p < 0.01, 
### p < 0.001 vs. 60 dpi; and $ p < 0.05, $$$ p < 0.001 
vs. 120 dpi. Outliers were detected using the GraphPad 
software QuickCalcs (p < 0.05). Graphic design was 
made with GraphPad Prism version 5.01 (La Jolla, 
CA, USA).
Results
Two-way ANOVA revealed a significant interaction 
between sCJD MM1-inoculation and the progression 
of the incubation time for aqp4 [F [2,16] = 6.960 
(P = 0.0058)], mpc1 [F [2,16] = 5.302 (P = 0.0154)], 
and mct4 [F [2,15] = 5.066 (P = 0.02)] gene expression 
(Figure 1a). Bonferroni’s post hoc test showed signifi-
cant differences between mice inoculated with human 
CJD MM1 homogenates and age-matched controls. 
Increased levels of aqp4 were found in inoculated ani-
mals at 160 dpi (P < 0.01) and 180 dpi (P < 0.000) when 
compared with age-matched controls. Similarly, signif-
icantly high levels of mpc1 mRNA were found in inocu-
lated animals at 180 dpi (P < 0.05) when compared 
with age-matched non-inoculated mice. Finally, high 
levels of mct4 were found in inoculated mice at 160 
dpi (P < 0.01) when compared with the corresponding 
control group.
Two-way ANOVA also revealed a significant effect 
of sCJD MM1-inoculation for gfap [F [1,16] = 17.49 
(P = 0.0006)] and slc1a2 [F [1,16] = 9.008 (P = 0.0077)] 
gene expression. Bonferroni’s post-hoc test showed 
increased levels of gfap in inoculated animals at 160 
dpi (P < 0.05), and 180 dpi (P < 0.05) when compared 
with age-matched non-inoculated mice. slc1a2 mRNA 
levels were significantly increased in inoculated animals 
at 160 dpi (P < 0.05) when compared with non- 
inoculated mice.
In contrast to gene expression alterations in astro-
cytes, the expression of olig1, cspg4 (encoding NG2), 
plp1, mbp, and mct1 did not show modifications when 
compared with controls up to 180 dpi; the only signifi-
cant interaction observed was between sCJD MM1- 
inoculation and the progression of the incubation 
time for myrf [F [2,16] = 4.295 (P = 0.03)] gene expres-
sion (Figure 1b). Bonferroni’s post hoc test indicated 
a significant increase in myrf expression levels at 180 
dpi (P < 0.05) when compared to the control group.
Spongiform changes were first observed at 120 dpi in 
the middle layers of the cerebral cortex, plexiform 
layers of the hippocampus, and striatum. The number 
of vacuoles in the neuropil increased at 180 dpi in all 
the cerebral cortex, hippocampus, dentate gyrus, sub-
iculum, thalamus, brain stem, cerebellum, and striatum.
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The morphological study was focused on the striatum 
because this was the most affected region in inoculated 
mice. Mild spongiform change occurred at 120 dpi and 
increased at 180 dpi (Figure 2a-d). A mild, non-significant 
increase in the number of astrocytes and microglial cells 
was noted at 120 dpi. A significant increase in the number 
of GFAP-immunoreactive astrocytes and Iba1-positive 
microglia appeared at 180 dpi (P = 0.000 and P = 0.000, 
respectively) (Figure 2e-l and Figure 3). The number of 
oligodendrocytes in the striatal fascicles showed 
a significant decrease at 180 dpi when compared to 0 and 
60 dpi animals (P = 0.01 and P = 0.004, respectively) 
Figure 1. Expression levels, as revealed by qPCR, of genes coding for specific proteins of astrocytes (a) and oligodendrocytes (b) in 
the cerebrum of tg340 control and tg340 sCJD MM1-inoculated mice at 0, 60, 120 (preclinical), and 180 (clinical stage) days post- 
inoculation (dpi). A significant increase in the expression of gfap and aqu4 is found at 160 and 180 dpi, whereas levels of mpc1, 
coding for mitochondrial pyruvate carrier 1, at 180 dpi, and mct4 and slc1a2, coding for monocarboxylic acid transporter member 4, 
and glial high affinity glutamate transporter, respectively, were significantly increased at 160 dpi with a trend not reaching statistical 
significance at 180 dpi. In contrast, expression levels of olig1, cspg4 (coding for NG2), plp1, mbp, and mog (coding for proteolipid 
protein 1, myelin basic protein, and myelin oligodendrocyte glycoprotein, respectively), did not show modifications up to 180 dpi. 
The levels of mct1 (coding for monocarboxylic acid transporter 1) were not affected. Only myrf was significantly increased at 180 dpi. 
Differences are considered statistically significant at * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 2. Morphology and immunohistochemistry of the striatum in tg340 control and tg340 sCJD MM1-inoculated mice at 0, 60, 
120 (preclinical), and 180 (clinical stage) days post-inoculation (dpi). A few vacuoles consistent with spongiform change are first seen 
in haematoxylin and eosin (H&E) stained sections at 120 dpi, and their number increases at 180 dpi (a-d). This is accompanied by 
a moderate, non-significant increase, in the number of reactive astrocytes and microglia at 120 dpi, and with marked increase of 
GFAP-immunoreactive cells (e-h) and microglia (Iba1-positive cells) (i-l) at 180 dpi. The number of oligodendrocytes, as revealed with 
the Olig2 antibody, shows a trend to decrease in the intrastriatal fibres at 180 dpi (m-p). The immunoreactivity to proteolipid protein 
1 (PLP1) is preserved at 180 dpi (q-t). Nevertheless, some intrastriatal fascicles show focal, cotton-like decrease of myelin basic 
protein (MBP) immunoreactivity at the same time-point (u-y). These alterations occur in parallel with the presence of PrPres 
immunoreactivity. A few punctate PrPres deposits are seen at 120 dpi; a diffuse synaptic-like PrPRes immunostaining are found at 
180dpi (z). Paraffin sections lightly counterstained with haematoxylin, A-P, bar = 25 μm; Q-Y, bar = 100 μm; Z, bar = 25 μm.
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(Figure 2m-p and Figure 3). No differences in immunos-
taining of proteolipid protein 1 (PLP1) were observed with 
disease progression up to 180 dpi (Figure 2q-t and Figure 
3). However, the immunoreactivity to myelin basic protein 
(MBP) focally decreased in the intrastriatal fascicles at 180 
dpi when compared to 60 dpi (P = 0.002) and 120 dpi 
(P = 0.036) animals (Figure 2u-y and Figure 3). These 
alterations occurred in parallel with the recognition of 
PrPRes immunostaining after inoculation. PrPRes immu-
noreactivity was first seen at 120 dpi as fine focal punctuate 
dots, and increased at 180 dpi as diffuse synaptic-like 
PrPRes deposits (Figure 2z).
Discussion
The present results confirm the widely recognized invol-
vement of astrocytes at early clinical stages of prion 
diseases, as revealed by the altered mRNA expression of 
many astrocyte markers at 160 dpi, and increased GFAP 
immunoreactivity at 180 dpi. The mRNA expression of 
oligodendroglial markers (olig1), adult oligodendroglial 
precursors (csp4), and genes encoding main myelin pro-
teins plp1, mbp, and mog [16–20] are not altered with 
disease progression up to 180 dpi. Only the expression of 
myelin regulatory factor (myrf) which triggers myelina-
tion is significantly increased at 180 dpi, thus suggesting 
some compensatory function to balance initial at-risk 
myelination linked to the decrease in the number of oli-
godendrocytes at 180 dpi. PLP1 immunostaining is not 
altered, but a focal cotton-like decrease of MBP occurs in 
the intrastriatal fascicles at 180 dpi. These findings corro-
borate the relative resistance of the oligodendrocyte cell 
line in comparison with the reaction of astrocytes and 
microglia to PrPSC in a validated model of human CJD. 
Figure 2. Continued.
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Nevertheless, our results also confirm that oligodendro-
cytes are vulnerable at advanced stages of murine CJD, as 
they have previously been noted to be in human sCJD 
[11–13].
Oligodendrocyte abnormalities may contribute to 
explain ultrastructural white matter myelin alterations in 
CJD, and other natural and experimentally induced animal 
prionopathies [11,21–23]. Moreover, oligodendrocyte 
alterations described in CJD [11–13] and present experi-
mental model may link transition between mild to moder-
ate white matter involvement in common forms compared 
with severe white matter involvement in panencephalo-
pathic forms of CJD [24–28]. Although alterations of the 
white matter parallel the intensity of lesions of the grey 
matter in cases with long duration of the disease [28,29], 
pioneering panencephalopathic cases, described principally 
in Japan, were in favour of a primary alteration of the white 
matter [24,30,31]. Myelin and nerve fibre loss accompanied 
by variable astrocyte proliferation and phagocytosis of mye-
lin debris is usually described in panencepaholopathic CJD, 
but, curiously, any information about oligodendrocytes in 
the white matter is almost disregarded. Nevertheless, 
engulfment of one or several oligodendrocytes by 
hypertrophic astrocytes (emperipolesis) was reported in 
five CJD cases with a long clinical course and devastated 
white matter [32]. Further studies are needed to elucidate 
astrocyte/oligodendrocyte interactions that sustain white 
matter alterations in CJD.
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Figure 3. Quantification of GFAP-, Iba1- and Olig2-immunoreactive cells, and MBP densitometry (arbitrary units) per area at different 
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